Table 1.
Clinical and demographic features of the STEMS-patients
| STEMS population | ||||
|---|---|---|---|---|
| Baseline | ||||
| Female Sex - n (%) | 8 (66.7) | |||
| Age (years) - Mean ± SD | 47.7 ± 4.9 | |||
| Disease type | ||||
| SPMS - n (%) | 5 (41.7) | |||
| PPMS - n (%) | 7 (58.3) | |||
| Disease Duration (years) - Mean ± SD | 14.6 ± 4.9 | |||
| Previous DMT - n (%) | ||||
| AZA | 2 (16.7) | |||
| MTX + CTX | 1 (8.3) | |||
| FTY | 4 (33.3) | |||
| RTX/OCR | 2 (16.7) | |||
| CTX | 1 (8.3) | |||
| DMF | 2 (16.7) | |||
| Time from last DMT to transplantation (years) - Mean ± SD | ||||
| 2.9 ± 1.8 | ||||
| Clinical and Neurophysiological assessment | Baseline (n = 12) | 2Y FU (n = 12) | LT FU (n = 11) | p value |
|---|---|---|---|---|
|
EDSS score (median [IQR]) |
7.25 [6.5-8.0] | 7.75 [7.0–8.0] | 8.5 [8.0–9.0] (n = 11) | LT vs. Baseline; LT vs. 2Y p < 0.01 |
|
SDMT score (median [IQR]) |
39.5 [34.3–51] | 50 [43–51] (n = 11) | 42 [32-46.3] (n = 10) | LT vs. Baseline p = 0.92; LT vs. 2Y p < 0.01 |
|
pRNFL thickness, µm (mean ± SD) |
91.2 ± 11.9 (n = 12) | 90.7 ± 13.3 (n = 11) | 92.9 ± 9 (n = 8) | LT vs. Baseline p = 0.05; LT vs. 2Y p = 0.3 |
SPMS: secondary progressive multiple sclerosis; PPMS: primary progressive multiple sclerosis; DMT: disease modifying therapy; AZA: azathioprine; MTX: Methotrexate; FTY: Fingolimod; RTX: rituximab; OCR: ocrelizumab; CTX: cyclophosphamide; DMF: Dimethyl Fumarate; EDSS: Expanded Disability Status Scale; IQR: Interquartile Range; SDMT: symbol digit modalities test; pRNFL: Peripapillary retinal nerve fiber layer